StemRIM
Notice Regarding Change of Representative Director (Increased Number of Directors)
Appoints the current CSO Katsuto Tamai as the representative director (CEO) and shifts to a two-person system with Obaoka Masatsune as co-leader. Discloses the new representative director’s biography and remarks on appointment.
Key Figures
- Name of the new Representative Director: Katsuto Tamai
- Effective date: 2026-09-09
- Old title: Representative Director and CEO → New title: Representative Director, Chairman and CSO
AI要約
Overview of the New Structure
As announced today by the board of directors, the company will transition to a two-person leadership with President and CEO Masatsune Obaoka and newly appointed Representative Director, Chairman and CSO Katsuto Tamai. This introduces a co-CEO structure to accelerate decision-making and strengthen the management foundation. Tamai will intensify his involvement as a founder and reinforce commitment to regenerative medicine R&D.
Biography and Remarks of the New Representative Director
Katsuto Tamai, born in 1960, has a long research and education career at Hirosaki University and Osaka University. Since 2012 he has served as CSO (current) on the company’s board, and since 2023 also served as invited professor at Osaka University. In appointing Tamai, he notes that his track record leading regenerative medicine R&D will accelerate drug discovery related to epidermolysis bullosa.
Stemrim
Company overview · Stock price · Financial data · All IR
